Neurological involvement in Wegener's granulomatosis

Current Opinion in Rheumatology

Volumn 23, Issue 1, 2011, Pages 7-11

  Holle, Julia U ^a   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

antineutrophil cytoplasmic antibody associated vasculitis; cranial nerve palsies; orbital masses; peripheral neuropathy; Wegener's granulomatosis; white matter lesions

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; RITUXIMAB;

ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; IMMUNE DEFICIENCY; MENINGITIS; NEUROLOGIC DISEASE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; WEGENER GRANULOMATOSIS;

EID: 78650490097     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834115f9     Document Type: Article

References (44)

1. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. New Engl J Med 2005; 352:330-332.
2. Reinhold-KellerE, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021-1032.
3. Drachman DA. Neurological complications of Wegener's granulomatosis. Arch Neurol 2001; 58:1215-1221.
4. Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 2010; 69:1934-1939.
5. Pagnoux C, Guillevin L Peripheral neuropathy in systemic vasculitides. Curr Opin Rheumatol 2005; 17:41-48.
6. De Groot K, Schmidt DK, Arlt AC, et al. Standardized neurologic evaluations of 128 patients with Wegener's granulomatosis. Arch Neurol 2001; 58:1215-1221.
7. Cattaneo L, Chierici E, Pavone L, et al. Peripheral neuropathy in Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry 2007; 78:1119-1123.
8. Nishino H, Rubino FA, DeRemee RA, et al. Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33:4-9.
9. Newman NJ, Slamovits TL, Friedland S, et al. Neuro-ophthalmic manifestations of meningocerebral inflammation from the limited forms of Wegener's granulomatosis. Am J Ophthalmol 1995; 120:613-621.
10. Nowack R, Wachtler P, Kunz J, et al. Cranial nerve palsy in Wegener's granulomatosis: lessons from clinical cases. J Neurol 2009; 256:199-304.
11. Anderson JM, Jamieson DG, Jefferson JM. Non-healing granuloma and the nervous system. Q J Med 1975; 44:309-323.
12. Illum P, Thorling K. Otological manifestations of Wegener's granulomatosis. Laryngoscope 1982; 92:801-804.
13. Hoffman GS, KerrGS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498.
14. Zhang W, Zhou G, Shi Q, et al. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 2009; 27 (1 Suppl 52):S65-S69.
15. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
16. Martin K, Bentaberry F, Dumoulin C, et al. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? Pharmacoepdemiol Drug Saf 2007; 16:74-78.
17. Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology 2007; 46:1087-1091.
18. Seror R, Mahr A, Ramanoelina J, et al. Central nervous system involvement in Wegener granulomatosis. Medicine 2006; 85:54-65.
19. Shiotani A, Mukobayashi C, Oohata H, et al. Wegener's granulomatosis with dural involvement as the initial clinical manifestation. Intern Med 1997; 36:514-516.
20. Choy DS, Weiss A, Lin PT. Progressive multifocal leukoencephalopathy following treatment for Wegener's granulomatosis. JAMA 1992; 268:600-601.
21. Haynes BF, Fishman ML, Fauci AS, et al. The ocular manifestations of Wegener's granulomatosis. Am J Med 1977; 63:131-141.
22. Foster WP, Greene JS, Millman B. Wegener's granulomatosis presenting as ophthalmoplegia and optic neuropathy. Otolaryngol Head Neck Surg 1995; 112:758-762.
23. Laudien M, Lamprecht P, Heddereich J, et al. Olfactory dysfunction in Wegener's granulomatosis. Rhinology 2009; 47:254-259.
24. Di Comite G, Bozzolo EP, Praderio L, et al. Meningeal involvement in Wegener's granulomatosis is associated with localized disease. Clin Exp Rheumatol 2006; 24 (2 Suppl 41):S60-S64.
25. Reinhold-KellerE, de Groot K, Holl-Ulrich K, et al. Severe CNS manifestations as the clinical hallmark in generalized Wegener's granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA): a report of 3 cases and review of the literature. Clin Exp Rheumatol 2001; 19:541-549.
26. Katrib A, Portek I, Corbet AJ, et al. Meningeal involvement in Wegener's granulomatosis. J Rheumatol 1998; 25:1009-1011.
27. Provenzale JM, Mukherji S, Allen NB, et al. Orbital involvement by Wegener's granulomatosis: imaging findings. AJR Am J Roentgenol 1996; 166:929-934.
28. Muhle C, Reinhold-Keller E, Richter G, et al. MRI of the nasal cavity, the paranasal sinuses and orbits in Wegener's granulomatosis. Eur Radiol 1997; 7:566-570.
29. Bullen CL, Liesegang TJ, McDonald TJ, et al. Ocular manifestations of Wegener's granulomatosis. Ophthalmology 2001; 108:1535-1543.
30. Fechner FP, Faquin WC, Pilch BZ. Wegener's granulomatosis of the orbit: a clinicopathological study of 15 patients. Laryngoscope 2002; 112:1945-1950.
31. Talar-WilliamsC, Sneller MC, Langford CA, et al. Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener's granulomatosis. Br J Ophthalmol 2005; 89:493-497.
32. Montecucco C, Caporali R, Pacchetti C, et al. Is Tolosa-Hunt syndrome a limited form of Wegener's granulomatosis? Report of two cases with antineutrophil cytoplasmic antibodies. Br J Rheumatol 1993; 32:640-641.
33. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93:433-439.
34. Bartolucci P, Ramanoelona J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002; 41:1126-1132.
35. Booth A, Harper L, Hammad T, et al. Prospective study of TNF alpha blockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-721.
36. Fujikawa K, Kawakami A, Eguchi K. Recovery from multiple cranial nerve palsy of Wegener's granulomatosis with infliximab. J Rheumatol 2008; 35:1471-1472.
37. Eriksson P. Nine patients with antineutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257:540-548.
38. Sharma A, Kunar S, Wanchu A, et al. Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab. Clin Rheumatol 2010; 29:107-110.
39. Bawa S, Mukthyar C, Edmonds S, et al. Refractory Wegener's meningitis treated with rituximab. J Rheumatol 2007; 34:900-901.
40. Hermann J, Reittner P, Scarpatetti M, et al. Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. Ann Rheum Dis 2006; 65:691-692.
41. Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60:1540-1547.
42. Martinez del Pero M, Chaudry A, Jones RB, et al. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009; 34:328-335.
43. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etenercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
44. Seo P, Min YI, Holbrook JT, et al. Damage caused by Wegener's granulomatosis and its treatment. Arthritis Rheum 2005; 52:2168-2178.